ArticleJournal of the American Chemical Society2017
Active Targeting of the Nucleus Using Nonpeptidic Boronate Tags.
Article in Journal of the American Chemical Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Nuclear-Targeted Drug Delivery Systems for Cancer Therapy: Advances, and Challenges.Molecules (Basel, Switzerland) · 2026Review
- Article
- Cancer Therapy with Polymeric Nanocarriers and the Transition to Targeted Cancer Therapy: Advances and Future Directions.Pharmaceutical nanotechnology · 2026Review
- Self-Assembly of Noncanonical Peptides: A New Frontier in Cancer Therapeutics and Beyond.Macromolecular bioscience · 2025Review
- Emerging magic bullet: subcellular organelle-targeted cancer therapy.Medical review (2021) · 2025Review
- Boron neutron capture therapy for melanoma: recent advances and future prospects.Frontiers in oncology · 2025Review
- Live-cell imaging of human apurinic/apyrimidinic endonuclease 1 in the nucleus and nucleolus using a chaperone@DNA probe.Nucleic acids research · 2024Article
- Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy.Medical oncology (Northwood, London, England) · 2024Article
- Targeting the organelle for radiosensitization in cancer radiotherapy.Asian journal of pharmaceutical sciences · 2024Review
- Current status, challenges and prospects of antifouling materials for oncology applications.Frontiers in oncology · 2024Review
- A light-activated polymer with excellent serum tolerance for intracellular protein delivery.Chemical science · 2023Article
- Intracellular delivery of therapeutic proteins. New advancements and future directions.Frontiers in bioengineering and biotechnology · 2023Review
- Intranuclear Nanoribbons for Selective Killing of Osteosarcoma Cells.Angewandte Chemie (International ed. in English) · 2022Article
- High affinity protein surface binding through co-engineering of nanoparticles and proteins.Nanoscale · 2022Article
- Protein Delivery: If Your GFP (or Other Small Protein) Is in the Cytosol, It Will Also Be in the Nucleus.Bioconjugate chemistry · 2021Review
- Dynamic Continuum of Nanoscale Peptide Assemblies Facilitates Endocytosis and Endosomal Escape.Nano letters · 2021Article
- Cellular- and Subcellular-Targeted Delivery Using a Simple All-in-One Polymeric Nanoassembly.Angewandte Chemie (International ed. in English) · 2020Article
- Azide-Terminated RAFT Polymers for Biological Applications.Current protocols in chemical biology · 2020Article
- Accessing Intracellular Targets through Nanocarrier-Mediated Cytosolic Protein Delivery.Trends in pharmacological sciences · 2020Review
- Cytosolic Delivery of Functional ProteinsACS applied materials & interfaces · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Active intracellular transport is a central mechanism in cell biology, directed by a limited set of naturally occurring signaling peptides. Here, we report the first nonpeptide moiety that recruits intracellular transport machinery for nuclear targeting. Proteins synthetically modified with a simple aromatic boronate motif are actively trafficked to the nucleus via the importin α/β pathway. Significantly, proteins too large to passively diffuse through nuclear pores were readily imported into the nucleus through this boronate-mediated pathway. The use of this simple motif to provide active intracellular targeting provides a promising strategy for directing subcellular localization for therapeutic and fundamental applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.